Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study

Feng,Hao; Yang,Zhibo; Bai,Xue; Yang,Meirong; Fang,Yuan; Zhang,Xiaonan; Guo,Qiqiang; Ning,Hong

doi:10.3892/ijmm.2018.3398

Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study

Authors:
- Hao Feng
- Zhibo Yang
- Xue Bai
- Meirong Yang
- Yuan Fang
- Xiaonan Zhang
- Qiqiang Guo
- Hong Ning
View Affiliations

Affiliations: Department of Ophthalmology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Ophthalmology, The Fourth People's Hospital of Shenyang, Shenyang, Liaoning 110001, P.R. China, Key Laboratory of Medical Cell Biology, College of Translational Medicine, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: January 18, 2018 https://doi.org/10.3892/ijmm.2018.3398
Pages: 2099-2107
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mammalian target of rapamycin (mTOR) serves a central role in regulating cell growth and survival, and has been demonstrated to be involved in the pathological progression of posterior capsule opacification (PCO). In the present study, the potency of PP242, a novel dual inhibitor of mTOR complex 1/2 (mTORC1/2), in the suppression of the growth of human lens epithelial cells (HLECs) was investigated. Using a Cell Counting Kit‑8 and a wound healing assay, it was demonstrated that PP242 inhibited the proliferation and migration of HLECs. In addition, western blot analysis indicated that PP242 completely inhibited mTORC1 and mTORC2 downstream signaling activities, whereas rapamycin only partially inhibited mTORC1 activity within LECs. Furthermore, PP242 treatment led to an upregulation of the expression levels of p53 and B cell lymphoma‑2 (Bcl‑2)‑associated X and downregulation of Bcl‑2. In addition, flow cytometric analysis demonstrated that PP242 induced the cell cycle arrest at the G0/G1 phase, which may have caused apoptosis and induced autophagy within the LECs. The results of the present study suggested that administration of PP242 may potentially offer a novel therapeutic approach for the prevention of PCO.

View Figures

View References

1	Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF, Tsai JC, Castaneda VE, Hoggatt JP and Kostick AM: Posterior capsule opacification. Surv Ophthalmol. 37:73–116. 1992. View Article : Google Scholar : PubMed/NCBI
2	Wormstone IM, Wang L and Liu CS: Posterior capsule opacification. Exp Eye Res. 88:257–269. 2009. View Article : Google Scholar
3	Awasthi N, Guo S and Wagner BJ: Posterior capsular opacification: A problem reduced but not yet eradicated. Arch Ophthalmol. 127:555–562. 2009. View Article : Google Scholar : PubMed/NCBI
4	Chan E, Mahroo OA and Spalton DJ: Complications of cataract surgery. Clin Exp Optom. 93:379–389. 2010. View Article : Google Scholar : PubMed/NCBI
5	Nishi O: Influence of intraocular lens material and design on the development of posterior capsule opacification. Ophthalmologe. 102:572–578. 2005.In German. View Article : Google Scholar : PubMed/NCBI
6	Nishi O, Yamamoto N, Nishi K and Nishi Y: Contact inhibition of migrating lens epithelial cells at the capsular bend created by a sharp-edged intraocular lens after cataract surgery. J Cataract Refract Surg. 33:1065–1070. 2007. View Article : Google Scholar : PubMed/NCBI
7	Apple DJ, Peng Q, Visessook N, Werner L, Pandey SK, Escobar-Gomez M, Ram J and Auffarth GU: Eradication of posterior capsule opacification: Documentation of a marked decrease in Nd:YAG laser posterior capsulotomy rates noted in an analysis of 5416 pseudophakic human eyes obtained postmortem. Ophthalmology. 108:505–518. 2001. View Article : Google Scholar : PubMed/NCBI
8	Javitt JC, Tielsch JM, Canner JK, Kolb MM, Sommer A and Steinberg EP: National outcomes of cataract extraction. Increased risk of retinal complications associated with Nd:YAG laser capsulotomy. The cataract patient outcomes research team. Ophthalmology. 99:1487–1498. 1992. View Article : Google Scholar : PubMed/NCBI
9	Nibourg LM, Gelens E, Kuijer R, Hooymans JM, van Kooten TG and Koopmans SA: Prevention of posterior capsular opacification. Exp Eye Res. 136:100–115. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zoncu R, Efeyan A and Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar
11	Guertin DA and Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005. View Article : Google Scholar : PubMed/NCBI
12	Cargnello M, Tcherkezian J and Roux PP: The expanding role of mTOR in cancer cell growth and proliferation. Mutagenesis. 30:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
13	Tian F, Dong L, Zhou Y, Shao Y, Li W, Zhang H and Wang F: Rapamycin-induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways. Int J Mol Sci. 15:13833–13848. 2014. View Article : Google Scholar : PubMed/NCBI
14	Xiong W, Cheng BH, Jia SB and Tang LS: Involvement of the PI3K/Akt signaling pathway in platelet-derived growth factor-induced migration of human lens epithelial cells. Curr Eye Res. 35:389–401. 2010. View Article : Google Scholar : PubMed/NCBI
15	Wederell ED and de Iongh RU: Extracellular matrix and integrin signaling in lens development and cataract. Semin Cell Dev Biol. 17:759–776. 2006. View Article : Google Scholar : PubMed/NCBI
16	Teo ZL, McQueen-Miscamble L, Turner K, Martinez G, Madakashira B, Dedhar S, Robinson ML and de Iongh RU: Integrin linked kinase (ILK) is required for lens epithelial cell survival, proliferation and differentiation. Exp Eye Res. 121:130–142. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sparks CA and Guertin DA: Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene. 29:3733–3744. 2010. View Article : Google Scholar : PubMed/NCBI
18	Schenone S, Brullo C, Musumeci F, Radi M and Botta M: ATP-competitive inhibitors of mTOR: An update. Curr Med Chem. 18:2995–3014. 2011. View Article : Google Scholar : PubMed/NCBI
19	Weber JD and Gutmann DH: Deconvoluting mTOR biology. Cell Cycle. 11:236–248. 2012. View Article : Google Scholar : PubMed/NCBI
20	Vousden KH and Prives C: Blinded by the Light: The growing complexity of p53. Cell. 137:413–431. 2009. View Article : Google Scholar : PubMed/NCBI
21	Chen Q, Ash JD, Branton P, Fromm L and Overbeek PA: Inhibition of crystallin expression and induction of apoptosis by lens-specific E1A expression in transgenic mice. Oncogene. 21:1028–1037. 2002. View Article : Google Scholar : PubMed/NCBI
22	Morgenbesser SD, Williams BO, Jacks T and DePinho RA: p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371:72–74. 1994. View Article : Google Scholar : PubMed/NCBI
23	Malecaze F, Decha A, Serre B, Penary M, Duboue M, Berg D, Levade T, Lubsen NH, Kremer EJ and Couderc B: Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells. Gene Ther. 13:440–448. 2006. View Article : Google Scholar
24	Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA and Swisher SG: Adenoviral Bak overexpression mediates caspase-dependent tumor killing. Cancer Res. 60:788–792. 2000.PubMed/NCBI
25	Zheng JH, Viacava Follis A, Kriwacki RW and Moldoveanu T: Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar
26	Munson MJ and Ganley IG: MTOR, PIK3C3, and autophagy: Signaling the beginning from the end. Autophagy. 11:2375–2376. 2015. View Article : Google Scholar : PubMed/NCBI
27	Wormstone IM and Eldred JA: Experimental models for posterior capsule opacification research. Exp Eye Res. 142:2–12. 2016. View Article : Google Scholar
28	Liegl R, Wertheimer C, Kernt M, Docheva D, Kampik A and Eibl-Lindner KH: Attenuation of human lens epithelial cell spreading, migration and contraction via downregulation of the PI3K/Akt pathway. Graefes Arch Clin Exp Ophthalmol. 252:285–292. 2014. View Article : Google Scholar
29	Laplante M and Sabatini DM: mTOR signaling at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
30	Guo R, Meng Q, Guo H, Xiao L, Yang X, Cui Y and Huang Y: TGF-β2 induces epithelial-mesenchymal transition in cultured human lens epithelial cells through activation of the PI3K/Akt/mTOR signaling pathway. Mol Med Rep. 13:1105–1110. 2016. View Article : Google Scholar
31	López-Novoa JM and Nieto MA: Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 1:303–314. 2009. View Article : Google Scholar
32	Liu Q, Thoreen C, Wang J, Sabatini D and Gray NS: mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg. 6:47–55. 2009. View Article : Google Scholar
33	Sehgal SN, Baker H and Vézina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 28:727–732. 1975. View Article : Google Scholar
34	Rao RD, Buckner JC and Sarkaria JN: Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets. 4:621–635. 2004. View Article : Google Scholar : PubMed/NCBI
35	Houghton PJ: Everolimus. Clin Cancer Res. 16:1368–1372. 2010. View Article : Google Scholar : PubMed/NCBI
36	Liu H, Feng G, Wu L, Fu S, Liu P, Yang W and Zhang X: The effects of rapamycin on lens epithelial cell proliferation, migration, and matrix formation: An in vitro study. Mol Vis. 16:1646–1653. 2010.PubMed/NCBI
37	Liu H, Wu L, Fu S, Hou Y, Liu P, Cui H, Liu J, Xing L and Zhang X: Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes. Graefes Arch Clin Exp Ophthalmol. 247:801–807. 2009. View Article : Google Scholar
38	Wang Z and Wang Z: Effects of rapamycin on expression of Bcl-2 and Bax in human lens epithelial cells and cell cycle in rats. J Huazhong Univ Sci Technolog Med Sci. 31:555–559. 2011. View Article : Google Scholar : PubMed/NCBI
39	Zhou HY and Huang SL: Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer. 31:8–18. 2012.
40	Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D and Shokat KM: Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7:e382009. View Article : Google Scholar : PubMed/NCBI
41	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
42	Osnes-Ringen Ø, Berg KH, Moe MC, Zetterström C, Røger M and Nicolaissen B: Cell death pattern in lens epithelium of cataract patients. Acta Ophthalmol. 94:514–520. 2016. View Article : Google Scholar : PubMed/NCBI
43	Li Y, Liu S, Zhang F, Jiang P, Wu X and Liang Y: Expression of the microRNAs hsa-miR-15a and hsa-miR-16-1 in lens epithelial cells of patients with age-related cataract. Int J Clin Exp Med. 8:2405–2410. 2015.PubMed/NCBI
44	Lin Z, McDermott A, Shao L, Kannan A, Morgan M, Stack BC Jr, Moreno M, Davis DA, Cornelius LA and Gao L: Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett. 344:272–281. 2014. View Article : Google Scholar :
45	Baehrecke EH: Autophagic programmed cell death in Drosophila. Cell Death Differ. 10:940–945. 2003. View Article : Google Scholar : PubMed/NCBI
46	Tresse E, Kosta A, Luciani MF and Golstein P: From autophagic to necrotic cell death in Dictyostelium. Semin Cancer Biol. 17:94–100. 2007. View Article : Google Scholar
47	Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, Baehrecke EH and Lenardo MJ: Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 304:1500–1502. 2004. View Article : Google Scholar : PubMed/NCBI
48	Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS and Shokat KM: Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 30:2219–2225. 2012. View Article : Google Scholar : PubMed/NCBI
49	Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, et al: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 16:205–213. 2010. View Article : Google Scholar : PubMed/NCBI